SEC Form 4 · accession 0001140361-15-008993
Relypsa Inc · RLYP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lance Berman
Officer — Chief Medical Officer and SVP
Period of report
Feb 24, 2015
Accepted (ET)
Feb 25, 2015 · 6:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001416792
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 24, 2015 | M | 1,580 | $3.96 | A | 9,080 | D | |
| Common StockF1 | Feb 24, 2015 | M | 1,580 | $3.96 | A | 10,660 | D | |
| Common StockF1 | Feb 24, 2015 | M | 1,840 | $7.40 | A | 12,500 | D | |
| Common StockF3,F1 | Feb 24, 2015 | S | 2,700 | $37.817 | D | 9,800 | D | |
| Common StockF4,F1 | Feb 24, 2015 | S | 2,300 | $38.6274 | D | 7,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $3.96 | Feb 24, 2015 | M | 1,580 | D | — | Dec 13, 2021 | Common Stock | 1,580 | 24,564 | D |
| Stock Option (right to buy)F6 | $3.96 | Feb 24, 2015 | M | 1,580 | D | — | Sep 27, 2022 | Common Stock | 1,580 | 33,114 | D |
| Stock Option (right to buy)F7 | $7.40 | Feb 24, 2015 | M | 1,840 | D | — | Jul 23, 2023 | Common Stock | 1,840 | 30,919 | D |
Explanation of responses
- F1Includes 7,500 restricted stock units.
- F2The sales reported in this Form 4 were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- F3This transaction was executed in multiple trades in prices ranging from $37.2693 to $38.23, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4This transaction was executed in multiple trades in prices ranging from $38.31 to $38.8943, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5The shares subject to the option are early exercisable. 25% of the shares subject to the option vest on the first anniversary measured from December 9, 2011 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.
- F6The shares subject to the option are early exercisable. 25% of the shares subject to the option vest on the first anniversary measured from September 19, 2012 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.
- F7The shares subject to the option are early exercisable. 25% of the shares subject to the option vest on the first anniversary measured from July 24, 2013 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.